Vivos Therapeutics Regains Compliance With Nasdaq Shareholders' Equity Requirement

• Nasdaq confirmed Vivos Therapeutics' compliance with its $2.5 million minimum stockholders' equity requirement on October 20, 2026, under Listing Rule 5550(b)(1).
• Compliance was restored following the acquisition of interests in SOD Sciences and its pseudohypoxia early-warning test.
• Failure to demonstrate compliance in the next periodic report could trigger delisting, subject to appeal to a Nasdaq Hearings Panel.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-047841), on October 21, 2026, and is solely responsible for the information contained therein.